Investments
75Portfolio Exits
11Funds
5Partners & Customers
1About VIMAC Ventures
VIMAC Ventures is the successor to VIMAC Corp. and VIMAC LP, which began funding startup companies in 1982. Based in Boston, the firm deploys capital in early-stage companies located in the eastern U.S. and Canada. It has two separate investment teamsâÂ"one focused on early stage ventures in IT/Adv.Materials technologies and the other focused on life sciences. The fund seeks to make about five new investments each year. A new investment typically goes into a Series A or Series B round with adequate reserves to support subsequent funding until the company exits via a trade sale or an IPO. Over its lifetime, a company is likely to receive $5 million to $15 million from the fund.
Latest VIMAC Ventures News
Aug 1, 2018
Angiochem secures $7.5M Series C Founded in 2003, Montreal based Angiochem has been backed by BDC Capital and VIMAC Ventures. photo credit: jarmoluk via pixabay News Release Proceeds to support ongoing development of ANG1005 for treatment of leptomeningeal carcinomatosis from breast cancer (Montreal – August 1, 2018) – Angiochem Inc. (“Angiochem”) announced today that it has secured a $7.5 million Series C financing to pursue its development plan. Angiochem is currently developing ANG1005 for the treatment of leptomeningeal carcinomatosis from breast cancer, for which there are no approved therapeutic treatment options currently available. Angiochem’s Phase 3 clinical trial for ANG1005 is expected to start later this year. “This is a significant development for Angiochem. With this latest financing, the company is on track to further develop ANG1005. This compound has already delivered promising results and now, we are gearing up for a pivotal Phase 3 trial that will hopefully lead to a long awaited therapeutic solution for patients with breast cancer who suffer from brain metastases and leptomeningeal carcinomatosis,” said John Huss, Executive Chairman of Angiochem. “This is an important, unmet medical need.” About Angiochem Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the brain blood barrier (BBB) to treat neurological diseases. These new compounds have the potential to address significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB. Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including primary brain cancer, brain metastases, lysosomal storage diseases and pain. Founded in 2003, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit http://www.angiochem.com. Contact Information:
VIMAC Ventures Investments
75 Investments
VIMAC Ventures has made 75 investments. Their latest investment was in CannaZia as part of their Unattributed on July 7, 2019.
VIMAC Ventures Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
7/3/2019 | Unattributed | CannaZia | $0.02M | Yes | 1 | |
6/26/2019 | Series B - II | SiteSpect | $1M | Yes | 1 | |
7/27/2018 | Unattributed VC | Remodel Health | $4M | Yes | 1 | |
7/10/2018 | Series D | |||||
12/30/2015 | Series C |
Date | 7/3/2019 | 6/26/2019 | 7/27/2018 | 7/10/2018 | 12/30/2015 |
|---|---|---|---|---|---|
Round | Unattributed | Series B - II | Unattributed VC | Series D | Series C |
Company | CannaZia | SiteSpect | Remodel Health | ||
Amount | $0.02M | $1M | $4M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | |||||
Sources | 1 | 1 | 1 |
VIMAC Ventures Portfolio Exits
11 Portfolio Exits
VIMAC Ventures has 11 portfolio exits. Their latest portfolio exit was Rapid Micro Biosystems on July 16, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
7/16/2021 | IPO | Public | 4 | ||
2/22/2016 | Acquired | 2 | |||
12/15/2011 | Acquired | ||||
Date | 7/16/2021 | 2/22/2016 | 12/15/2011 | ||
|---|---|---|---|---|---|
Exit | IPO | Acquired | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 4 | 2 |
VIMAC Ventures Fund History
5 Fund Histories
VIMAC Ventures has 5 funds, including VIMAC III LP.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
12/31/2006 | VIMAC III LP | Early-Stage Venture Capital | Closed | $150M | 1 |
1/25/2005 | VIMAC Milestone Medica | ||||
12/31/2001 | VIMAC Early Stage Fund II LP | ||||
10/31/1999 | VIMAC IT II | ||||
10/31/1999 | VIMAC I |
Closing Date | 12/31/2006 | 1/25/2005 | 12/31/2001 | 10/31/1999 | 10/31/1999 |
|---|---|---|---|---|---|
Fund | VIMAC III LP | VIMAC Milestone Medica | VIMAC Early Stage Fund II LP | VIMAC IT II | VIMAC I |
Fund Type | Early-Stage Venture Capital | ||||
Status | Closed | ||||
Amount | $150M | ||||
Sources | 1 |
VIMAC Ventures Partners & Customers
1 Partners and customers
VIMAC Ventures has 1 strategic partners and customers. VIMAC Ventures recently partnered with MaRS Discovery District on May 5, 2004.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
5/17/2004 | Vendor | Canada | MaRS takes big step in establishing Toronto as a major global R&D - News release NPS Pharmaceuticals and VIMAC Ventures LLC , a venture capital firm active in biosciences , have selected MaRS as the ideal global destination to pursue research and commercial opportunities in the fast-emerging medical and related technology fields . | 2 |
Date | 5/17/2004 |
|---|---|
Type | Vendor |
Business Partner | |
Country | Canada |
News Snippet | MaRS takes big step in establishing Toronto as a major global R&D - News release NPS Pharmaceuticals and VIMAC Ventures LLC , a venture capital firm active in biosciences , have selected MaRS as the ideal global destination to pursue research and commercial opportunities in the fast-emerging medical and related technology fields . |
Sources | 2 |
VIMAC Ventures Team
10 Team Members
VIMAC Ventures has 10 team members, including current Managing Director, Sena K. Biswas.
Name | Work History | Title | Status |
|---|---|---|---|
Sena K. Biswas | Managing Director | Current | |
Name | Sena K. Biswas | ||||
|---|---|---|---|---|---|
Work History | |||||
Title | Managing Director | ||||
Status | Current |
Loading...